公开(公告)号：US20170190669A1

公开(公告)日：2017-07-06

申请号：US15312998

申请日：2015-05-20

Applicant: ABIDE THERAPEUTICS, INC. ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Dale L. BOGER ,  Katerina OTRUBOVA ,  Justin S. CISAR ,  Cheryl A. GRICE ,  Todd K. JONES

IPC: C07D231/14 ,  C07D491/107 ,  C07D403/12 ,  C07D417/12 ,  C07D405/12 ,  C07D401/12

CPC classification number: C07D231/14 ,  C07D231/12 ,  C07D231/16 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12 ,  C07D491/10 ,  C07D491/107

Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of one or more of MAGL, ABHD6, and FAAH. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain, solid tumors and/or obesity.

公开(公告)号：US20170183353A1

公开(公告)日：2017-06-29

申请号：US15313012

申请日：2015-05-20

Applicant: ABIDE THERAPEUTICS, INC. ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Benjamin F. CRAVATT ,  Armand B. COGNETTA ,  Jonathan J. HULCE ,  Micah J. NIPHAKIS ,  Todd K. JONES ,  Cheryl A. GRICE

IPC: C07D487/04 ,  C12Q1/34

CPC classification number: C07D487/04 ,  C12Q1/34

Abstract: Provided herein are N-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases. Furthermore, the subject compounds and compositions are useful for the treatment of one or more of cancer, pain, diabetes, obesity/metabolic syndrome, epilepsy, traumatic brain injury, and inflammation.

公开(公告)号：US20170073320A1

公开(公告)日：2017-03-16

申请号：US15272313

申请日：2016-09-21

Applicant: Abide Therapeutics, Inc.

Inventor： Justin S. CISAR ,  Cheryl A. GRICE ,  Todd K. JONES ,  Micah J. NIPHAKIS ,  Jae Won CHANG ,  Kenneth M. LUM ,  Benjamin F. CRAVATT

IPC: C07D295/205 ,  C07D307/79 ,  C07D215/46 ,  C07D295/26 ,  C07D263/32 ,  C07D231/56 ,  C07D213/38 ,  C07D413/10 ,  C07D403/10 ,  C07D401/10 ,  C07D231/12 ,  C07D207/14 ,  C07D231/16 ,  C07D491/107 ,  C07D471/10 ,  C07D205/04 ,  C07D471/04 ,  C07D487/04 ,  C07D317/58

CPC classification number: C07D295/205 ,  C07C271/10 ,  C07C271/12 ,  C07D205/04 ,  C07D207/09 ,  C07D207/14 ,  C07D213/38 ,  C07D213/40 ,  C07D213/55 ,  C07D215/42 ,  C07D215/46 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D295/26 ,  C07D307/79 ,  C07D317/46 ,  C07D317/58 ,  C07D401/04 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D407/06 ,  C07D413/06 ,  C07D413/10 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107

Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from indications such as pain, solid tumor cancer and/or obesity comprising administering a disclosed compound or composition.

Abstract translation: 本公开提供了可以是MAGL和/或ABHD6的调节剂的化合物和组合物及其作为药物的用途，其制备方法和包含公开的化合物作为至少一种活性剂的药物组合物。 本公开还提供了治疗有需要的患者的方法，其中患者患有诸如疼痛，实体瘤癌症和/或肥胖的适应症，其包括施用所公开的化合物或组合物。